



### "ALEXANDRU IOAN CUZA" UNIVERSITY OF IAȘI FACULTY OF CHEMISTRY DOCTORAL SCHOOL OF CHEMISTRY AND LIFE AND EARTH SCIENCES

### LILIANA LUCESCU

### FIVE AND SIX-MEMBERED NITROGEN-CONTAINING HETEROCYCLES. SYNTHESIS AND APPLICATIONS

PHD THESIS SUMMARY


SCIENTIFIC COORDINATOR, Prof. Univ. Dr. ELENA BÎCU

This work was supported by the strategic Grant POSDRU/159/1.5/S/137750, Project 'Doctoral and Postdoctoral programs support for increased competitiveness in Exact Sciences research' cofinanced by the European Social Fund within the Sectorial Operational Program Human Resources Development 2007–2013.

### **OBJECTIVES**

The heterocyclic combinations represent as far the biggest class of compounds in organic chemistry and have a great importance due the biological and industrial applications. Particularly, 1,3,5-triazine (or *s*-triazine) is the six-membered aromatic cycle with 3 nitrogen atoms, which represent the base of a well-known class of compounds, that continue to be the subject of important studies, due their numerous applications in different areas.

In the thesis we proposed the implementation of some structural modulation of 4,6-dimethoxy-1,3,5-triazinic cycle, which consist in binding in position 2 of some five or six-membered nitrogencontaining heterocycles, found in the structure of compounds with recognized pharmacological properties, in order to create a synergy of effects, that lead to improved biological properties.



Scheme 1. Research directions

The established objectives of this thesis are following:

I. Synthesis, characterisation, study of reactivity and biological evaluation of some new triazinpyrrolidones derivatives;

II. Synthesis, characterisation and biological evaluation of some new triazin-triazoles derivatives;

III. Synthesis, characterisation and biological evaluation of some new triazin-indolizines derivatives;

IV. Synthesis, characterisation and biological evaluation of some new triazin-isoxazoles derivatives;


V. Study of the reactivity of 2-ethynyl-4,6-dimethoxy-1,3,5-triazine with amines.

### **PERSONAL RESERCHES**

### I. Synthesis, characterisation, study of reactivity and biological evaluation of some new triazin-pyrrolidones derivatives


### I.3.1. The total hydrolysis of methoxy groups

By heating the dimethoxytriazines **14a-e** at reflux temperature in aqueous hydrochloric acid (1.8%) for five hours furnished a 47-85% yield of triazinediones **15a-e.** Interestingly, during these reactions with hydrochloric acid, partial hydrolysis or migration of a methyl group were not detected.




Scheme 7. The total hydrolysis of methoxy groups

Table 3. The synthesized 2-substituted triazin-4,6-diones
---



### I.3.2. The partial hydrolysis of methoxy groups

By heating dimethoxytriazines 14a-c,e at reflux temperature in the presence of potassium hydroxide (1–2 equiv) in methanol for 20–28 hours to give 60–87% yields (Table 4) of 2-methoxy-1,3,5-triazin-6-ones 16a-c,e. No by-products were isolated from these reactions.




Scheme 8. The partial hydrolysis of methoxy groups

Compound	Structure	η %	Compound	Structure	η %
16a		80	16c		73
16b		87	<b>16</b> e		62

Tabelul 4. The synthesized 2-substituted 2-methoxy-1,3,5-triazin-6-ones

### I.3.3. Hilbert-Johnson migration

The dimethoxytriazines **14a** and **14c** were heated at reflux temperature in toluene in the presence of dimethyl sulfate for 24–28 hours to give 1,3-dimethyl-1,3,5-triazines **17a** and **17c** (Scheme 9); again, no by-products were isolated from these reactions.



Scheme 9. Hilbert-Johnson migration

Compound	Structure	<b>η</b> %
17a		52
17c		46


Products **15a,c** and **16b,c** were selected by the National Cancer Institute (NCI) for a biological screening on a 60-cell line panel, but the results were modests. The antifungal properties of these compounds will be reported in due course.

The results of this study represent the subject of a scientific publication<sup>157</sup>: *Studies on Pyrrolidinones: Chemistry of Dimethoxytriazines,* **Liliana Lucescu**, Philippe Gautret, Souhila Oudir, Benoît Rigo, Dalila Belei, Elena Bîcu, Alina Ghinet, *Synthesis*.

### II. Synthesis, characterisation and biological evaluation of some new triazin-triazoles derivatives


### II.4. Synthesis strategies

The synthetic way adopted for obtaining the target hybrid compounds starts with 1,3,5-triazine cyclization, followed by 1,2,3-triazole ring closing, as it described in scheme 14.




Scheme 14. The second synthetic strategie adopted for the access to triazinil-triazoles derivatives

The synthetic pathway started from propiolic acid **39**, which after activation as acid chloride **38**, by treatement with phosphorus pentachloride,<sup>178</sup> reacted with salt **8** and furnished the target acetylenic derivative **37** (Scheme 15)



Scheme 15. The synthetic pathway for 2-ethynyl-4,6-dimehtoxy-1,3,5-triazine

The last step of our synthesis was represented by the catalytic ring-closing of 1,2,3-triazole unit, using a *click chemistry* reaction with acetylenic derivative **37** and azides **32a-i** (Scheme 17).



Scheme 17. Triazinyl-triazoles 41a-i synthesis

Tabl	Table 8. The synthetized triazinyl-triazoles							
Compound	Structure	η %	Compound	Structure	η %			
41a	F C OMe	52	41f	NC N:N N NC N NC OMe	43			
41b		65	41g	$\begin{array}{c} \bigcirc & 0 & N \\ \searrow & N & N & N \\ N & N & N & N \\ S & & OMe \end{array}$	61			
41c	O N:N N N Br OMe	58	41h	$\begin{array}{c c} O & N \\ &$	83			
41d	Me O N:N N N O Me O Me O Me O Me O Me	38	41i	$ \overbrace{\overset{N}{\swarrow}\overset{N}{\overset{N}}}^{O} \underset{\overset{N}{\overset{N}}\overset{N}{\overset{N}}}{\overset{N}{\overset{N}}} \underset{\overset{N}{\overset{N}}\overset{O}{\overset{N}}}{\overset{N}{\overset{N}}} \underset{\overset{N}{\overset{N}}}{\overset{O}{\overset{N}}} \underset{\overset{N}{\overset{N}}}{\overset{O}{\overset{O}{\overset{N}}}} $	26			
41e	0 N:N N → OMe MeO → N → N → N → N MeO → OMe OMe	79						

### II.5. Biological evaluation

The activity of newly triazin–triazoles **41a-i** was evaluated on *farnesyltransferase* (FTase) as a potential zinc chelating moiety. The best result of the study were obtained for *p*-bromophenyl derivative **41c** and *p*-chlorophenyl derivative **41b**.

Compound	FTase% <sup>a,b</sup>	IC <sub>50</sub> (μM)	Compound	FTase%	IC <sub>50</sub> (µM)
<b>41</b> a	19	_c	<b>41f</b>	37	-
<b>41b</b>	59	72,05±6,9	41g	0	-
<b>41c</b>	73	38,62±1,7	<b>41h</b>	35	-
<b>41d</b>	48	-	<b>41i</b>	24	-
41e	0	-			

**Table 9.** Results of the human *farnesyltransferase* assay

 $^a$  Inhibition ratio of protein farnesyltransferase at a 100  $\mu M$  concentration

<sup>b</sup> Values represent mean of two experiments


<sup>c</sup> Not determined.

The results of this study represent the subject of a scientific publication:<sup>184</sup> Synthesis and biological evaluation of a new class of triazin-triazoles as potential inhibitors of human farnesyltransferase, Liliana Lucescu, Elena Bîcu, Dalila Belei, Sergiu Shova, Benoît Rigo, Philippe Gautret, Joëlle Dubois, Alina Ghinet, Research on Chemical Intermediates.

## III. Synthesis, characterisation and biological evaluation of some new triazin-indolizines derivatives


### IIIA. Benzoyl-triazin-indolizines derivatives

The target compounds were obtained in two steps, as described in scheme 18. First of all we synthesized the pyridinium salts, which next participated to a 1,3-dipolar cycloaddition reaction with 2-ethynyl-4,6-dimentoxy-1,3,5-triazine **37**, previously synthesized.




Scheme 18. The synthetic pathway for target benzoyl-triazin-indolizines

The construction of the indolizine unit in products **64a-s** achieved by reaction of the corresponding ylide, generated *in situ* by base treatment of pyridinium salts **63a-s**, with 2-ethynyl-4,6-dimehtoxy-1,3,5-triazine **37** (Scheme 20).



Scheme 20. The construction of indolizine unit

Compound	Structure	η %	Compound	Structure	<b>η</b> %
64a	MeO MeO OMe N N N N OMe N N N OMe	58	64k		47
64b	MeO OMe OMe NEO MeO	51	641		52



28 of synthesized indolizines, were selected by the National Cancer Institute (NCI) for a biological screening on the NCI-60 cell lines panel and the results are summarized in tables 14 and 15. These results showed that the presence of dimethoxytriazine cycle is esential for bioactivity. The most promising candidate of the study was **64m**, with a  $GI_{50}$  value of 870 nM on SNB-75 CNS cancer cells and of 920 nM on MDA-MB-231/ATCC breast cancer.

By using the program NCI COMPARE for the most active derivative of our study **64m**, led to interesting results, which showed a correlation of 0,942 with an inhibitor of PLK1 (polo-like kinase 1).

	Compound	64a	64b	64c	64d	64e	64f	64g	64h	64
Panel	Cell line									
Leukemia	CCRF-CEM	_ <sup>a</sup>	10	26	62	-	-	13	-	11
	HL-60(TB)	-	33	60	-	-	-	-	-	-
	K-562	10	45	56	29	-	-	-	-	-
	RPMI-8226	-	10	30	52	-	-	26	-	13
	SR	20	67	74	29	19	13	22	-	26
Non-small cell lung	A549/ATCC	-	17	36	28	21	-	-	11	21
cancer	HOP-62	-	34	28	-	97	25	-	60	77
	NCI-H460	-	-	16	14	-	-	-	-	20
	NCI-H522	-	56	43	11	60	-	-	21	47
Colon cancer	HCT-116	-	15	27	-	36	-	12	-	26
CNS cancer	SF-295	-	15	-	40	47	-	-	47	33
	SNB-75	-	67	58	23	-17	46	18	-14	-3
	U251	-	-	15	-	56	-	-	6	44
Melanoma	MALME-3M	11	37	61	-	-	-	-	17	30
	MDA-MB-435	35	86	100	-	-	-	-	-	-
	SK-MEL-5	-	41	63	67	-	-	19	-	-
	UACC-62	-	30	63	9	11	-	-	14	14
Ovarian cancer	OVCAR-3	-	19	75	28	-	-	-	-	-
	OVCAR-8	-	12	15	41	16	-	-	14	24
	NCI/ADR-RES	-	15	24	38	9	-	-		-
	SK-OV-3	-	8	29	-	54	-	-	42	55
Renal cancer	786-0	-	-	20	-	27	-	-	40	31
	ACHN	-	30	47	0	4	-	-	15	56
	RXF 393	-	31	41	15	9	14	-	52	37
Prostate cancer	PC-3	-	19	36	37	8	-	13	-	19
Breast cancer	MCF7	-	55	73	22	13	-	10	-	19
	MDA-MB-	-	17	25	23	-	18	35	39	43
	231/ATCC									
	HS 578T	-	17	35	14	25	16	-	42	46

Table 14. In vitro percentage of growth inhibition caused by the compounds 64a-h,l at 10  $\mu M$  concentration

<sup>a</sup>GI%<10%

	Compus	64m	64n	640	64q	64r	64s
Panel	Cell line						
Leukemia	K-562	22	_ <sup>a</sup>	-	-	-	-
	RPMI-8226	26	-	-	-	-	-
	SR	36	-	-	-	-	-
Non-small cell lung	A549/ATCC	62	-	-	-	49	55
cancer	HOP-62	96	-	-	-	79	-
	HOP-92	59	-	-	-	-	-
	NCI-H226	75	-	-	-	35	28
	NCI-H460	70	-	-	-	68	71
Colon cancer	HCT-116	65	-	-	-	-	-
CNS cancer	SF-295	87	22	20	-	59	76
	SF-539	76	-	-	-	-	-
	SNB-75	-5	75	-	27	69	75
	U251	61	-	-	-	-	-
Melanoma	MALME-3M	37	18	73	-	58	67
	SK-MEL-28	63	14	30	-	43	52
	UACC-257	62	-	31	11	30	32
	UACC-62	30	-	-	-	-	-
Ovarian cancer	OVCAR-3	44	15	-	-	31	51
	OVCAR-4	88	18	95	-	30	33
	OVCAR-8	52	29	-	-	50	50
	NCI/ADR-RES	50	14	-	-	43	46
	SK-OV-3	-11	20	-	-	-	-
Renal cancer	786-0	59	14	-	-	45	81
	ACHN	70	30	-	-	22	29
	CAKI-1	56	-	-	-	33	44
	RXF 393	75	36		14	61	81
	TK-10	78	-	-	-	-	-
Prostate cancer	PC-3	55	-	-	-	37	58
Breast cancer	MCF7	18	24	38	-	44	60
	MDA-MB-	48	27	-	11	80	96
	231/ATCC						
	HS 578T	96	22	-	-	56	65
	T-47D	52	19	-	-	31	38

Tabelul 15 In vitro	percentage of grou	wth inhibition caused b	v 64m-0 0	<b>n-s</b> at 10	uM concentration
	percentage of gro	win minorition caused t	/y 0 <del>4</del> m-0,0	-5 at 10	

<sup>a</sup>GI%<10%


#### Five and six-membered nitrogen-containing heterocycles. Synthesis and applications

The results of this study represent the subject of two scientific papers,<sup>209,210</sup> a published one and a submitted one:

- 1. Discovery of indolizines containing triazine moiety as new leads for the development of antitumoral agents targeting mitotic events, Liliana Lucescu, Alina Ghinet, Dalila Belei, Benoît Rigo, Joëlle Dubois, Elena Bîcu, Bioorganic & Medicinal Chemistry Letters.
- Synthesis and biological evaluation of some new indolizine derivatives as antitumoral agents, Liliana Lucescu, Elena Bîcu, Dalila Belei, Joëlle Dubois, Alina Ghinet, Letters in Drug Design and Discovery.


### IIIB. Indazoyl-triazin-indolizines

The synthesis of target hybrids indazoyl-triazin-indolizines was achieved in four steps. The first step consisted in indazol cyclization 91, using *o*-toluidines 90 as starting material. The resulting indazoles participated to an acylation reaction with chloroacetyl chloride. The pyridinium salts 94 were obtained by reacting the acylated derivatives 92 with different pyridines. In the last stage, the construction of indolizine unit was accomplished.



Scheme 27. The synthetic pathway for target indazoyl-triazin-indolizines derivatives 95

Target indolizines **95a-m** and **96c-h,j-m** were obtained by [3+2] cycloaddition reaction of the corresponding ylide, generated *in situ* by triethylamine treatment of pyridinium salts **94a-m**, with 2-ethynyl-4,6-dimethoxy-1,3,5-triazine **37** (Scheme 30) or ethyl propiolate (Scheme 31).



Schema 30. The construction of indolizine unit with 2-ethynyl-4,6-dimethoxy-1,3,5-triazine 37





 Table 21. The synthesized indazoyl-triazinyl-indolizines hybrids 95a-m



Scheme 31. The construction of indolizine unit with ethyl propiolate

Compound	Structure	η %	Compound	Structure	η %
96c		57	96h		59
96d	Br OMe N N O OEt	26	96j	$CI \xrightarrow{\mathbf{N}}_{N} \xrightarrow{\mathbf{N}}_{N} \xrightarrow{\mathbf{N}}_{\mathbf{N}} \xrightarrow{\mathbf{N}}_{\mathbf{O}} \mathbf{M} \mathbf{e}$	34
96e		44	96k		43
96f	Br O N N O OEt	57	961	$\bigcup_{N=1}^{CI} \bigcup_{N=1}^{O} \bigcup_{N=1}^{N} Me$	44
96g	Br N N OEt	45	96m	$\begin{array}{c} C \\ \downarrow \\ N \\ N \\ N \\ \downarrow \\ N \\ \downarrow \\ O \\ O$	48

Table 22. The synthesized 1-carboxyethyl substituted indolizines 96c-h,j-m

Our previous results concerning the ability of indolizine derivatives as *farnesyltransferase* inhibitors,<sup>224</sup> encouraged us to test the new indolizinyl-indazole derivatives on this enzyme. The best results for this assay were obtained in the 1-(4,6-dimethoxy-1,3,5-triazinyl)-indolizines serie.

The results from the NCI biological assay revealed a strong antiproliferative activity and a cytotoxic activity against the cell line OVCAR-4, for compound **96c**.

Compound	%Ftase <sup>a,b</sup>	IC <sub>50</sub> FTase (µM)	Compound	%Ftase <sup>a,b</sup>	IC <sub>50</sub> FTase (µM)
95a	68,31	52,50±16,07	95j	39,88	nd
95b	12,09	nd <sup>c</sup>	95k	86,45	nd
95c	58,46	nd	951	60,19	nd
95d	70,37	58,60±16,79	95m	51,37	nd
95e	82,36	27,08±4,93	96f	24,82	nd
95f	5,53	nd	96g	37,70	nd
95h	67,03	nd	96h	11,14	nd
95i	55,84	nd	96k	55,80	nd

Table 23. Results of the human farnesyltransferase assay


<sup>a</sup>Inhibition ratio of protein *farnesyltransferase* at a 100  $\mu$ M concentration

<sup>b</sup>Values represent mean of two experiments

°Not determined.


# IV. Synthesis, characterisation and biological evaluation of some new triazin-isoxazoles derivatives

The synthesis of target isoxazole derivatives **113a-m** was achieved in two steps. We started with oximes **112** preparation, using suitable substituted benzaldehyde **111** and hydroxylamine hydrochloride. The last step consisted in the construction of isoxazole unit.



Scheme 32. The synthetic pathway for target triazinyl-isoxazole derivatives 113

For the preparation of isoxazole unit in compounds **113a-m** and **114c** we utilized a 1,3-dipolar cycloaddition, realised *one-pot* with oximes **112a-m**, 2-ethynyl-4,6-dimethoxy-1,3,5-triazine **37** or ethyl propiolate as dipolarophile.<sup>236</sup>



Scheme 34. One-pote synthesis of triazinyl-isoxazole derivatives 113a-m

Compound	Structure	η %	Compound	Structure	η %
113a	MeO N-O N-OMe MeO N-N MeO OMe	27	113h		56
113b	MeO OMe OMe	67	113i	Br OMe	21
113c	MeO N-O N-OMe MeO N-N-N OMe OMe	42	113j	N-O N-OMe N-O N-OMe Cl	31
113d	MeO OMe	27	113k	$C_{1} N O N O N O N O N O N O N O N O N O N $	71

Table 26. The synthesized triazinyl-isoxazole derivatives 113a-m and 114c

113e	Me Ne OMe	25	1131	Cl N-O N-OMe N-V N-V Cl OMe	5
113f	N-O N-OMe N-O N-N OMe OMe	23	113m	N-O N-OMe N N N N OMe	42
113g		64	114c	MeO OEt	

The reaction proved to be a regioselective one, independent on electronic effects of dipolarophile substituents, leading each time to 3,5-disubstituted-isomer. The confirmation of reaction regioselectivity was achieved through RX diffraction.




Figure 26. The structures of compounds 113i and 113k determined by RX diffraction

In order to identify the biological targets of the synthesized compounds, they were tested for the inhibitory capacity against human *farneziltrasferase*. In general, the compounds showed a modest activity, except the derivatives **114c** and **113**.

Compound	%Ftase <sup>a,b</sup>	IC <sub>50</sub> FTase (µM)	Compound	%Ftase	IC <sub>50</sub> FTase (µM)
11 <b>3</b> a	28,15	n.d. <sup>c</sup>	113h	33,22	n.d.
113b	17,05	n.d.	113i	31,47	n.d.
113c	0	n.d.	113j	34,52	n.d.
113d	0	n.d.	113k	52,78	n.d.
113e	0	n.d.	1131	86,16	37,31±4,18
113f	13,84	n.d.	113m	24,64	n.d.
113g	0	n.d.	114c	87,47	37,22±12,75

 Table 27. Results of the human farnesyltransferase assay

<sup>a</sup>Inhibition ratio of protein *farnesyltransferase* at a 100 µM concentration

<sup>b</sup>Values represent mean of two experiments


°Not determined.

# V. Study of the reactivity of 2-ethynyl-4,6-dimethoxy-1,3,5-triazine with various amines

### V.2. The reaction of 2-ethynyl-4,6-dimethoxy-1,3,5-triazine with anilines

After the reactions of acethylenic derivative **37** with secondary amines were identified two products, corresponding to *cis* and *trans* isomers of expected enamine. Particularly, after the reaction with anilines **115c-e,i,k,n-p**, a quinoline derivative was also observed (Scheme 41).

Opposite theory, the Z-isomer was more stable, while E-isomer is converting in time in corresponding Z-isomer. This is explained by the intramolecular hydrogen bond formed whitin NH group and one nitrogen atom from trazine cycle.



Scheme 41. The reaction of 2-ethynyl-4,6-dimethoxy-1,3,5-triazine with various anilines




Figure 31. <sup>1</sup>H NMR spectra of isomers 116c and 118c

Table 28. The synthesized Z-enamines derivatives 116c-p							
Compound	Structure	η %	Compound	Structure	ղ %		
116c	MeO-N-HN-OMe N=OMe OMe	25	116j		44		
116d	MeO N OMe	6*	116k	MeO- N- N- OMe	56		
116e		28	1161		45		
116f		46	116m		40		
116g	MeO MeO N N OMe	56	116n		38		
116h		59	1160		49		
116i	MeO - N - MN - OMe OMe	28*	<b>116</b> p	MeO-N-N-Me OMe Me	*		

\*Observed in the <sup>1</sup>H NMR spectrum of the crude reaction, not isolated.

### Table 29. The synthesized 3-(4,6-dimethoxy-1,3,5-triazinyl)-quinolines 117c-e,i,k,n-p

Compus	Structură	η %	η	Compus	Structură	η %	η
			RMN%				RMN%
117c	OMe OMe MeO MeO N	58	58	117k	MeO HO N N OMe	27	50
117d	OMe NeO MeO N	29	29	117n	OMe N N O N OMe	12	25
117e	OMe OMe N MeO N	60	85	1170		72	85
117i		<5	5	117p	OMe N Me·N Me	5	45

Some of the synthesized compounds were biological evaluated for inhibitory ability on human *farnesyltransferase* and for anti-tubulin activity and the results are listed in table 32. The results obtained from the bioassays were promising, highlighting the high potential of these compounds capable to interact with both biological targets.

Compound	%TPI <sup>a</sup>	IC <sub>50</sub> Tubuline (µM)	%FTase <sup>b</sup>	IC <sub>50</sub> Ftase (µM)
116a	14	n.d. <sup>c</sup>	54	n.d.
116b	53	n.d.	53	n.d.
116c	65,60	44,23±1.97	101,41	11,59±1,98
116e	47,34	n.d.	n.d.	n.d.
116f	23,64	n.d.	n.d.	n.d.
116g	70,65	25,17±2,64	101,95	9,56±0,68
116h	68,56	42,28±2,40	110,76	7,03±0,5
116j	74,34	33,93±2,56	47	n.d.
116k	67,74	96,01±9,83	n.d.	n.d.
116m	27,11	n.d.	n.d.	n.d.
116n	39,20	n.d.	n.d.	n.d.
1160	70,90	84,48±12,06	n.d.	n.d.
117c	23,56	n.d	0	n.d.
117d	22,5	n.d.	103,66	3,01±0,42
117e	0	n.d.	n.d.	n.d.
117k	0	n.d.	n.d.	n.d.
117p	11,41	n.d.	n.d.	n.d.

Table 32. Inhibitory activities on tubulin polymerization and *farnesyltransferaze* 

<sup>a</sup>Inhibition ratio of tubulin polymerization at a 100  $\mu$ M concentration.

<sup>b</sup>Inhibition ratio of protein *farnesyltransferase* at a 100 µM concentration.

°Not determined.

### **GENERAL CONCLUSIONS**

The various biological properties of triazines, along with their promising anti-tumor potential, influenced us to direct our investigations to this area.

• During the three years of study, different structural modulation were performed at 1,3,5triazine cycle, aiming to generate new compounds with improved biological properties. Thus, we synthesized a total number of 216 compounds, of which **157 new, not mentioned in the literature**.

The resulting compounds were purified and then characterized by IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>19</sup>F NMR, MS spectra, by elemental analysis and by RX diffraction. The results of spectra analysis are summarized in the chapter entitle "Experimental section".

The main research directions addressed are the following:

- 1. Synthesis, characterisation, study of reactivity and biological evaluation of some new triazin-pyrrolidones derivatives;
- 2. Synthesis, characterisation and biological evaluation of some new triazin-triazoles derivatives
- 3. Synthesis, characterisation and biological evaluation of some new triazin-indolizines derivatives;
- 4. Synthesis, characterisation and biological evaluation of some new triazin-isoxazoles derivatives;
- 5. Study of the reactivity of 2-ethynyl-4,6-dimethoxy-1,3,5-triazine with amines
- Out of the synthesized compounds in this study, a total of 54 participated in the biological screening developed by the NCI, 11 compounds showed inhibitory activity against *farneziltrasferase* enzyme and 6 compounds have shown promising ability to inhibit tubulin polymerization.
  - The information obtained after all the investigations carried out, allowed us to establish a series of structure-biological activity relationships, that can represent the starting point for the design of novel triazine potential biological actives.
  - A part of the results of the research carried out during PhD studies represent the subject of four ISI scientific publications, three published and one submitted for publication and some oral communications and posters presented at some national and international conferences.

### Scientific publications:

- Studies on Pyrrolidinones: Chemistry of Dimethoxytriazines, Liliana Lucescu, Philippe Gautret, Souhila Oudir, Benoît Rigo, Dalila Belei, Elena Bîcu, Alina Ghinet, Synthesis, 2013, 45, 1333-1340.
- Synthesis and biological evaluation of a new class of triazin-triazoles as potential inhibitors of human farnesyltransferase, Liliana Lucescu, Elena Bîcu, Dalila Belei, Sergiu Shova, Benoît Rigo, Philippe Gautret, Joëlle Dubois, Alina Ghinet, *Research on Chemical Intermediates* 2015, doi 10.1007/s11164-015-2131-1.
- Discovery of indolizin-triazines as new leads for the development of antitumoral agents targeting mitotic events, Liliana Lucescu, Alina Ghinet, Dalila Belei, Benoît Rigo, Joëlle Dubois, Elena Bîcu, Bioorganic & Medicinal Chemistry Letters, 2015, 25, 3975-3979.
- Synthesis and biological evaluation of some new indolizine derivatives as antitumoral agents, Liliana Lucescu, Elena Bîcu, Dalila Belei, Joëlle Dubois, Alina Ghinet, Letters in Drug Design and Descovery, 2015 submitted manuscris.

### REFERENCES

Oudir, S.; Rigo, B.; Hénichart, J.-P.; Gautret, P. Synthesis (Stuttg). 2006, 2006, 2845–2848.

Lucescu, L.; Gautret, P.; Oudir, S.; Rigo, B.; Belei, D.; Bîcu, E.; Ghinet, A. Synth. 2013, 45, 1333–1340.

Belei, D.; Bicu, E.; Jones, P. G.; Birsa, M. L. J. Heterocycl. Chem. 2011, 48, 129–134.

Belei, D.; Dumea, C.; Samson, A.; Farce, A.; Dubois, J.; Bîcu, E.; Ghinet, A. *Bioorg. Med. Chem. Lett.* **2012**, 22, 4517–4522.

Brooke, G. M.; Matthews, R. S.; Harman, M. E.; Hursthouse, M. B. J. Fluor. Chem. 1991, 53, 339–354.

Lucescu, L.; Bîcu, E.; Belei, D.; Shova, S.; Rigo, B.; Gautret, P.; Dubois, J.; Ghinet, A. *Res. Chem. Intermed.* 2015, http://dx.doi.org/10.1007/s11164-015-2131-1.

Abuhaie, C.-M.; Bîcu, E.; Rigo, B.; Gautret, P.; Belei, D.; Farce, A.; Dubois, J.; Ghinet, A. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 147–152.

Ghinet, A.; Abuhaie, C.-M.; Gautret, P.; Rigo, B.; Dubois, J.; Farce, A.; Belei, D.; Bîcu, E. *Eur. J. Med. Chem.* **2015**, *89*, 115–127.

Belei, D.; Abuhaie, C.; Bicu, E.; Jones, P. G.; Hopf, H.; Birsa, L. M. Synlett 2012, 545–548.

Arnautu, A.; Collot, V.; Ros, J. C.; Alayrac, C.; Witulski, B.; Rault, S. *Tetrahedron Lett.* **2002**, *43*, 2695–2697.

Dumea, C.; Belei, D.; Ghinet, A.; Dubois, J.; Farce, A.; Bîcu, E. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 5777–5781.

Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V; Noodleman, L.; Sharpless, K. B.; Fokin, V. V *J. Am. Chem. Soc.* **2005**, *127*, 210–216.

Lucescu, L.; Ghinet, A.; Belei, D.; Rigo, B.; Dubois, J.; Bîcu, E. *Bioorg. Med. Chem. Lett.* 2015, 25, 3975–3979.

Lucescu, L.; Bîcu, E.; Belei, D.; Dubois, J.; Ghinet, A. Lett. Drug Des. Descovery 2015, submitted manuscript.